A Case of Complete Recovery in a Hypereosinophilic Dermatitis Patient with Dupilumab

Xiaoyun Jiang,Jun Ye,Xia Wu,Jiang Zhu,Siji Chen,Hao Cheng
DOI: https://doi.org/10.1007/s00011-023-01715-1
IF: 6.986
2023-01-01
Inflammation Research
Abstract:Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED. We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed. After using dupilumab, the patient’s condition significantly improved with the glucocorticoid dosing decreased successfully. In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose.
What problem does this paper attempt to address?